ESPR

Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (CVD) and are struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines to lower the risk of myocardial infarction and coronary revascularization in adults with primary hyperlipidemia. Its NEXLETOL is an ATP Citrate Lyase (ACLY), inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.

Wall Street analysts forecast ESPR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ESPR is 6.94 USD with a low forecast of 1.72 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Esperion Therapeutics Inc revenue for the last quarter amounts to 87.31M USD, increased 69.10 % YoY.

Esperion Therapeutics Inc. EPS for the last quarter amounts to -0.16 USD, increased 6.67 % YoY.

Esperion Therapeutics Inc (ESPR) has 304 emplpoyees as of January 10 2026.

Today ESPR has the market capitalization of 927.57M USD.